Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Long Georgina V.; Atkinson Victoria; Cebon Jonathan S.; Jameson Michael B.; Fitzharris Bernie M.; McNeil Catriona M.; Hill Andrew G.; Ribas Antoni; Atkins Michael B.; Thompson John A.; Hwu Wen-Jen; Hodi F. Stephen; Menzies Alexander M.; Guminski Alexander D.; Kefford Richard; Kong Benjamin Y.; Tamjid Babak; Srivastava Archana; Lomax Anna J.; Islam Mohammed; Shu Xinxin; Ebbinghaus Scot; Ibrahim Nageatte; Carlino Matteo S.

首页> 外文期刊>The lancet oncology >Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

【24h】

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

机译：标准剂量Pembrolizumab与患有先进黑素瘤的患者的减少剂量IPILIMIMAB（Keynote-029）：开放标签，第1B期试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Reduced-dose nivolumab in combination with standard-dose ipilimumab improves objective response and progression-free survival compared with standard-dose ipilimumab alone, but increases toxicity. We assessed the safety and anti-tumour activity of standard-dose pembrolizumab in combination with reduced-dose ipilimumab.

机译：背景技术与单独的标准剂量IPILIMIMAB相比，减少剂量Nivolumab与标准剂量IPILIMIMAB组合改善了客观反应和无进展的存活率，但增加了毒性。我们评估了标准剂量Pembrolizumab的安全性和抗肿瘤活性与减少剂量IPILIMIMAB组合。

著录项

来源
《The lancet oncology》 |2017年第9期|共9页
作者
Long Georgina V.; Atkinson Victoria; Cebon Jonathan S.; Jameson Michael B.; Fitzharris Bernie M.; McNeil Catriona M.; Hill Andrew G.; Ribas Antoni; Atkins Michael B.; Thompson John A.; Hwu Wen-Jen; Hodi F. Stephen; Menzies Alexander M.; Guminski Alexander D.; Kefford Richard; Kong Benjamin Y.; Tamjid Babak; Srivastava Archana; Lomax Anna J.; Islam Mohammed; Shu Xinxin; Ebbinghaus Scot; Ibrahim Nageatte; Carlino Matteo S.;
展开▼
作者单位

Univ Sydney Mater Hosp Melanoma Inst Australia Sydney NSW Australia;

Greenslopes Private Hosp Gallipoli Med Res Fdn Greenslopes Qld Australia;

La Trobe Univ Austin Hlth Sch Canc Med Olivia Newton John Canc Res Inst Heidelberg Vic;

Waikato Hosp Reg Canc Ctr Hamilton New Zealand;

Christchurch Hosp Canterbury Dist Hlth Board Christchurch New Zealand;

Univ Sydney Royal Prince Alfred Hosp Melanoma Inst Australia Sydney NSW Australia;

Tasman Oncol Res Gold Coast Qld Australia;

Univ Calif Los Angeles Dept Med Los Angeles CA 90024 USA;

Georgetown Lombardi Comprehens Canc Ctr Washington DC USA;

Univ Washington Dept Med Seattle WA USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

Dana Farber Canc Inst Boston MA 02115 USA;

Univ Sydney Mater Hosp Melanoma Inst Australia Sydney NSW Australia;

Univ Sydney Mater Hosp Melanoma Inst Australia Sydney NSW Australia;

Macquarie Univ Westmead Hosp Melanoma Inst Australia Sydney NSW Australia;

Westmead Hosp Westmead NSW Australia;

La Trobe Univ Austin Hlth Sch Canc Med Olivia Newton John Canc Res Inst Heidelberg Vic;

Waikato Hosp Reg Canc Ctr Hamilton New Zealand;

Univ Sydney Royal Prince Alfred Hosp Melanoma Inst Australia Sydney NSW Australia;

Tasman Oncol Res Gold Coast Qld Australia;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Merck &

Co Inc Kenilworth NJ USA;

Westmead Hosp Westmead NSW Australia;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial [J] . Long Georgina V., Atkinson Victoria, Cebon Jonathan S., The lancet oncology . 2017,第9期

机译：标准剂量Pembrolizumab与患有先进黑素瘤的患者的减少剂量IPILIMIMAB（Keynote-029）：开放标签，第1B期试验
2. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study [J] . Atkins Michael B., Hodi F. Stephen, Thompson John A., Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第8期

机译：PEMBROLIZUMAB加聚乙二醇化干扰素ALFA-2B或IPILIMIMAB用于高级黑素瘤或肾细胞癌：DESE-IB keynote-029研究的结果结果
3. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial [J] . Atkins Michael B., Plimack Elizabeth R., Puzanov Igor, The lancet oncology . 2018,第3期

机译：Axitinib与Pembrolizumab联合患者患有先进的肾细胞癌：非随机性，开放标签，剂量发现和剂量扩展阶段1B试验
4. Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients [C] . Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, . 2010

机译：使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
5. Communication preferences, expectations of benefit, and symptom burdens among advanced cancer patients and partners during patient participation in phase I trials [D] . Hlubocky, Fay J. 2010

机译：患者参加I期试验期间，晚期癌症患者及其伴侣之间的沟通偏好，受益期望以及症状负担
6. Randomized Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Unresectable Melanoma [O] . Jason Chesney, Igor Puzanov, Frances Collichio, -1

机译：评估Talimogene Laherparepvec联合Ipilimumab与单独Ipilimumab联合治疗晚期无法切除的黑色素瘤的疗效和安全性的随机开放标签II期临床研究
7. Phase 1 results of a phase 1b/2, multicenter, open-label trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) vs ipi alone in previously untreated, unresected stage IIIB-IV melanoma [O] . Igor Puzanov, Mohammed Milhem, Robert Andtbacka, 2013

机译：1b / 2期，多中心，开放标签试验的1期结果，用于评估talimogene laherparepvec（T-VEC）和ipilimumab（ipi）与单独ipi在先前未经治疗，未切除的IIIB-IV期黑色素瘤中的安全性和有效性

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

摘要

著录项

相似文献

相关主题

期刊订阅